Literature DB >> 17169244

The PROACTIVE Study and reduction of cardiovascular events in patients with diabetes.

Michael H Davidson.   

Abstract

Entities:  

Year:  2007        PMID： 17169244     DOI： 10.1007/bf02693939

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  12 in total

1.  Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Authors:  Robert H Knopp; Michael d'Emden; Johan G Smilde; Stuart J Pocock
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

2.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Authors:  H C Gerstein; S Yusuf; J Bosch; J Pogue; P Sheridan; N Dinccag; M Hanefeld; B Hoogwerf; M Laakso; V Mohan; J Shaw; B Zinman; R R Holman
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

3.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study).

Authors:  Stewart B Harris; Jean-Marie Ekoé; Yola Zdanowicz; Susan Webster-Bogaert
Journal:  Diabetes Res Clin Pract       Date:  2005-10       Impact factor: 5.602

5.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Authors:  Ronald B Goldberg; David M Kendall; Mark A Deeg; John B Buse; Anthony J Zagar; Jane A Pinaire; Meng H Tan; Mehmood A Khan; Alfonso T Perez; Scott J Jacober
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

6.  Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

Authors:  Alexander Tenenbaum; Michael Motro; Enrique Z Fisman; David Tanne; Valentina Boyko; Solomon Behar
Journal:  Arch Intern Med       Date:  2005-05-23

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.

Authors:  Kaoruko Tada Iida; Yasushi Kawakami; Masatsune Suzuki; Hitoshi Shimano; Hideo Toyoshima; Hirohito Sone; Kazunori Shimada; Yoshitaka Iwama; Yoshiro Watanabe; Hiroshi Mokuno; Katsuo Kamata; Nobuhiro Yamada
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-02-04       Impact factor: 4.310

10.  Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Authors:  R Scott; J Best; P Forder; M-R Taskinen; J Simes; P Barter; A Keech
Journal:  Cardiovasc Diabetol       Date:  2005-08-22       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.